Mometadex (Mometasone Furoate Ph. Eur.)

Mometasone furoate binds to glucocorticoid receptors in the nasal lining, altering gene expression to suppress inflammatory cytokines, reduce vascular leakage, and limit leukocyte migration. This localized anti‑inflammatory action provides symptom relief while minimizing systemic exposure.

The prescribed dose of Mometadex is determined by the treating clinician based on the patient’s age, severity of symptoms, and response to therapy. Patients should follow the specific dosing instructions provided on the prescription label.

Safety data for Mometadex in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting treatment.

To request Mometadex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometadex contains mometasone furoate, a high‑potency corticosteroid with minimal systemic absorption, similar to other nasal steroids such as fluticasone propionate. Its efficacy in reducing nasal inflammation is comparable, while its once‑daily dosing and low systemic bioavailability are often highlighted advantages.

Mometadex should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid freezing the product.

Mometadex is administered as a nasal spray. The patient should gently blow the nose, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The same procedure is repeated in the other nostril if directed by the prescriber.

Serious risks, though rare, include nasal septal perforation, severe allergic reactions (anaphylaxis), adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal passages. Patients should report any unusual symptoms to their healthcare provider promptly.

Mometadex should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation, and in patients with active untreated nasal infections. Caution is also advised for those with uncontrolled glaucoma, cataracts, or systemic fungal infections.